Personal Finance

Why Celldex Therapeutics, Inc. Stock Jumped Higher Again Today

Image source: Getty Images.

What happened

Shares of Celldex Therapuetics (NASDAQ: CLDX) are up 10.5% at 3:37 p.m. EST after the biotech presented data on CDX-1140 at the Society for Immunotherapy of Cancer (SITC) annual meeting on Saturday.

So what

You're forgiven if you've never heard of CDX-1140; the drug hasn't started clinical studies yet. The preclinical data presented at SITC showed that the drug could bind to its target, CD40, turning on the receptor that activates the immune system, which can then attack a tumor. Celldex is completing the preclinical development for CDX-1140, with plans to start clinical development next year. The ultimate plan is to test CDX-1140 in combination with other immunotherapies or conventional cancer treatments.

Normally preclinical data wouldn't send shares up by a double-digit percentage, but these aren't ordinary times. The biotech sector is still enjoying some post-election euphoria since Hillary Clinton won't be able to lower drug prices. And for Celldex specifically, the biotech has been quite volatile lately as it waits for data from its two lead drugs, glembatumumab vedotin and varlilumab. Shares made another double-digit jump last week after what appeared to be a news-less earnings report.

Now what

Long-term investors can ignore the moves up -- and likely some future news-less moves down -- because none of it really matters to the long-term valuation, which will be defined by whether glembatumumab vedotin and varlilumab make it to market.

Forget the 2016 Election: 10 stocks we like better than Celldex Therapeutics

Donald Trump was just elected president, and volatility is up. But here's why you should ignore the election:

Investing geniuses Tom and David Gardner have spent a long time beating the market no matter who's in the White House. In fact, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Celldex Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as ofNovember 7, 2016.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Celldex Therapeutics. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Personal Finance Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More